181 related articles for article (PubMed ID: 18466425)
21. What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation?
Lamoth F; Manuel O; Venetz JP; Faouzi M; Meylan P; Pascual M
Transplantation; 2008 Nov; 86(9):1323-4. PubMed ID: 19005418
[No Abstract] [Full Text] [Related]
22. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
23. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir.
Fellay J; Venetz JP; Pascual M; Aubert JD; Seudoux C; Meylan PR
Am J Transplant; 2005 Jul; 5(7):1781-2; author reply 1783. PubMed ID: 15943640
[No Abstract] [Full Text] [Related]
24. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
[TBL] [Abstract][Full Text] [Related]
25. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management.
Hanson KE; Swaminathan S
Future Microbiol; 2015; 10(10):1545-8. PubMed ID: 26437628
[No Abstract] [Full Text] [Related]
27. [Cytomegalovirus infection in transplant recipients].
Gondo H
Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
[TBL] [Abstract][Full Text] [Related]
28. [Hexal expands its antiviral portfolio].
Red
MMW Fortschr Med; 2016 May; 158(10):90. PubMed ID: 27221453
[No Abstract] [Full Text] [Related]
29. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
30. [Cytomegalovirus infections in transplant patients].
Charpentier B
Presse Med; 1991 Jun; 20(24):1107-8. PubMed ID: 1649473
[No Abstract] [Full Text] [Related]
31. Benefits of cytomegalovirus prophylaxis in solid organ transplantation.
Pescovitz MD
Transplantation; 2006 Jul; 82(2 Suppl):S4-8. PubMed ID: 16858270
[TBL] [Abstract][Full Text] [Related]
32. Prophylaxis against fungal infections and cytomegalovirus disease after bone marrow transplantation.
Wilkin A; Feinberg J
Oncology (Williston Park); 2000 Dec; 14(12):1701-8; discussion 1708, passim. PubMed ID: 11212856
[TBL] [Abstract][Full Text] [Related]
33. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
[TBL] [Abstract][Full Text] [Related]
34. Management of CMV infection and disease in transplant patients. 27-29 February 2004.
Razonable RR; Emery VC;
Herpes; 2004 Dec; 11(3):77-86. PubMed ID: 15960905
[TBL] [Abstract][Full Text] [Related]
35. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
[TBL] [Abstract][Full Text] [Related]
37. Preemptive therapy for cytomegalovirus.
Singh N; Yu VL
Liver Transpl; 2006 Feb; 12(2):327. PubMed ID: 16447192
[No Abstract] [Full Text] [Related]
38. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines.
Le Page AK; Jager MM; Kotton CN; Simoons-Smit A; Rawlinson WD
Transplantation; 2013 Jun; 95(12):1455-60. PubMed ID: 23640298
[TBL] [Abstract][Full Text] [Related]
39. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
40. Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation.
El Helou G; Razonable RR
Expert Opin Drug Saf; 2019 Nov; 18(11):1017-1030. PubMed ID: 31478398
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
